Neutrophil Extracellular Trap Components Associate with Infarct Size, Ventricular Function, and Clinical Outcome in STEMI
Table 5
Hazard ratios for experiencing an adverse clinical event during 12-month follow-up.
HR
95% CI
Age, per year
0.98
0.94–1.02
0.294
Male gender
0.7
0.2–1.8
0.420
Ischemic postconditioning
0.5
0.2–1.3
0.179
Time, symptoms to PCI (ln), per SD
1.1
0.7–1.7
0.737
Peak troponin T (ln), per SD
1.7
1.0–2.8
0.037
Peak CRP (ln), per SD
3.1
1.7–5.5
<0.001
Baseline NT-proBNP (ln), per SD
1.1
0.7–1.8
0.650
TIMI risk score, per point
1.3
1.1–1.6
0.016
High dsDNA before PCI
2.9
1.0–8.0
0.043
Adjusted for peak troponin T
2.6
0.9–7.3
0.065
Adjusted for peak CRP
2.4
0.8–6.8
0.105
Adjusted for TIMI risk score
2.7
1.0–7.6
0.057
High dsDNA on day 1
5.9
1.7–20.3
0.005
Adjusted for male gender
6.7
1.9–23.2
0.003
Adjusted for peak troponin T
5.1
1.4–18.4
0.012
Adjusted for peak CRP
3.5
1.0–12.5
0.058
Adjusted for TIMI risk score
5.2
1.5–18.1
0.009
High dsDNA is defined as >median (before PCI: >452 ng/ml; day 1: >367 ng/ml). Adverse clinical event is defined as a composite of all-cause mortality, myocardial infarction, , rehospitalization for heart failure, or stroke. CI: confidence interval. CRP: C-reactive protein. HR: hazard ratio. PCI: percutaneous coronary intervention. SD: standard deviation. TIMI: thrombolysis in myocardial infarction.
